Blocking red blood cell death after brain hemorrhage
Official title: Inhibition of Erythrocyte Ferroptosis as a Therapeutic Target after Intracerebral Hemorrhage
Funded at Yale University · NIH-11450183 · Data updated 2026-11-12
A study at Yale is exploring whether stopping a specific kind of red blood cell death after a brain hemorrhage could improve recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 1, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $667,613 |
| NIH project number | 1R01NS147128-01A1 |
| Project ID | NIH-11450183 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients who have experienced an intracerebral hemorrhage and meet specific clinical criteria related to early post-hemorrhage care and safety screening.
✕Less likely to help
Individuals without intracerebral hemorrhage or those not meeting safety criteria would not benefit from this study.
What this research studies
After an intracerebral hemorrhage, iron and blood products can harm the brain. This project looks at ferroptosis, a programmed death process in red blood cells, and how heme might trigger it within the clot. Researchers will test pathways and drugs that might delay red blood cell breakdown to reduce damage and improve outcomes. The work combines lab experiments with steps toward translating findings into therapies for patients who have had a brain bleed.
Why it matters
Potential benefit: If successful, the work could lead to new treatments that lessen brain damage and improve recovery after brain hemorrhage.
How similar studies have gone: Previous research on ferroptosis and iron-related brain injury supports the potential of this approach, but applying it to erythrocyte death after ICH is a novel direction.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Sansing, Lauren H — Yale University
- Study coordinator: Sansing, Lauren H
Related research
Other NIH-funded projects on the same topics.
-
Anticoagulation in ICH Survivors with Atrial Fibrillation and Small Vessel Disease
This project looks at how to safely use blood-thinning medicines in people who survived a brain bleed and also have atrial fibrillation and small vessel disease.
-
Statin use after lobar intracerebral hemorrhage
This trial compares continuing versus stopping statins in people who had a lobar intracerebral hemorrhage to see how that affects repeat brain bleeds, strokes, heart attacks, and recovery over two years.
-
Statin use after lobar brain hemorrhage
This trial compares stopping versus continuing statin medicine in people who had a lobar brain bleed to learn effects on repeat bleeding and future heart or stroke events.
-
Targeting HDAC3 to reduce brain damage after a brain bleed
This project will test whether blocking a protein called HDAC3 can reduce inflammation and improve recovery after an intracerebral hemorrhage (brain bleed).
-
Silent brain injuries after brain bleed may predict dementia risk
A study using MRI and cognitive tests to see if hidden brain injuries after spontaneous intracerebral hemorrhage help forecast later cognitive decline.
-
Tracking how stem cells and their tiny vesicles move in a mouse model of brain bleed
A study in mice will map how stem cells and their extracellular vesicles distribute in the brain after an intracerebral hemorrhage to better understand how they could help repair the damaged brain.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.